New drug aims to shield transplanted livers from immune attack
Disease control
Recruiting now
This early study tests whether siplizumab can safely prevent the immune system from attacking a new liver in people with autoimmune hepatitis or primary sclerosing cholangitis. Eight participants will receive two doses of the drug around the time of transplant and be monitored fo…
Phase: PHASE1 • Sponsor: Elizabeth C. Verna • Aim: Disease control
Last updated May 17, 2026 03:59 UTC